Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
about
Sanfilippo syndrome: causes, consequences, and treatmentsPathophysiology of heparan sulphate: many diseases, few drugsNewborn screening and diagnosis of mucopolysaccharidosesAn integrated approach using orthogonal analytical techniques to characterize heparan sulfate structureNeurodevelopmental Changes in Excitatory Synaptic Structure and Function in the Cerebral Cortex of Sanfilippo Syndrome IIIA MiceRecent advances in cellular glycomic analyses.Glycosaminoglycans detection methods: Applications of mass spectrometry.Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.Establishment of glycosaminoglycan assays for mucopolysaccharidosesDelivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.Heparan sulfate inhibits hematopoietic stem and progenitor cell migration and engraftment in mucopolysaccharidosis I.Identification of chondroitin sulfate linkage region glycopeptides reveals prohormones as a novel class of proteoglycansAmyloidosis, synucleinopathy, and prion encephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood.Newborn screening for lysosomal storage diseasesSpecific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice.A genetic model of substrate reduction therapy for mucopolysaccharidosis.Diagnosing mucopolysaccharidosis IVANeonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.Glycan-based biomarkers for mucopolysaccharidoses.Lysosomal diseases: diagnostic update.Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB.Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-HClearance of Heparan Sulfate and Attenuation of CNS Pathology by Intracerebroventricular BMN 250 in Sanfilippo Type B Mice.Site-specific identification of heparan and chondroitin sulfate glycosaminoglycans in hybrid proteoglycans.Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient.Disease correction by combined neonatal intracranial AAV and systemic lentiviral gene therapy in Sanfilippo Syndrome type B mice.Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.Arylsulfatase K is the Lysosomal 2-Sulfoglucuronate Sulfatase.Identification and structural characterization of novel O- and N-glycoforms in the urine of a Schindler disease patient by Orbitrap mass spectrometry.Expanding the chondroitin glycoproteome of Caenorhabditis elegans.Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometry.Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses.Fast, sensitive method for trisaccharide biomarker detection in mucopolysaccharidosis type 1.Lysosomal Proteome and Secretome Analysis Identifies Missorted Enzymes and Their Nondegraded Substrates in Mucolipidosis III Mouse Cells
P2860
Q26773200-63E4AA7F-AF21-4357-A8BE-6FFFCC9C5586Q26823840-0119157C-10A8-48A1-9234-9A53E25D8BFAQ27025080-F3B1EEB7-A0A4-4EE7-A4AA-CF8390E7C665Q28818221-CA5EAC71-4A3A-41F7-ABAB-95605905B83BQ33572735-A8B3AEC1-894C-4849-BBB7-079B6A186FADQ33649651-C944A569-1887-40C8-BC64-412CCF6CE1CCQ33816146-B276FAFA-28BA-4AD6-B92A-9647758D5D55Q34005906-219CF68E-A4C9-440D-B2F5-75D6007757AFQ34318230-A6195486-E222-4E95-A25A-0E9451DBB294Q34384222-45367AB3-CE18-4FDD-90AA-3F43E2DB8FFCQ34774580-3617348E-4E8F-405B-9DD5-8A2733D788CEQ34884277-546F0A0D-6AD2-4133-B882-31BAE63AE1C1Q35053456-C574E7CD-251E-46FD-AFBD-F8C468309CDEQ35134207-B2F8A02B-6AB7-4127-A803-D7C0863F832DQ35911463-1A3A20B9-A7DE-415A-B348-65834F783A34Q36068878-A47D0829-DCA0-478A-B4D4-301F9B8A6D9BQ36332885-34603696-34DD-45C5-8419-43AC63452F2EQ36662855-BE40713D-AA12-43C9-963E-F909EFD09CF9Q36757021-32F85C46-3073-4385-B5E1-0B6B37D10FE9Q37161285-989DCFA4-2025-4446-A652-529B4DFC97C6Q38202920-E9389C20-DB2E-4914-B2EE-7FB6C864D54FQ38851110-5C972397-9B38-455A-AEC0-53D286C514F1Q38988296-A63A385B-E41C-4F74-A728-389AF4F4AAB9Q39136670-0D9AF291-933B-41B8-A4EB-E37259659FD8Q40482507-C477DB53-69D5-46FB-A560-48CE24A9683CQ41267661-C6534B4B-706E-4671-9758-1D977EC5B962Q41775393-629BB46D-38B7-4828-A993-722B8964AA93Q42090139-EB3E8E1C-F869-4541-A067-AFB22854FB13Q43106648-51442776-67DF-4A05-9737-D239ACF5299CQ45931498-4A1D759C-8D7E-4E58-9083-F321E988D471Q46018872-CFCCEA60-2F0E-4413-A101-8378DE022D75Q46791866-416DC3CA-2DA7-4190-A40B-95EDE27D9548Q47402381-CB5BF7C4-1931-496E-99AB-A1FAB843423EQ48484381-59439517-2F6B-447F-9293-896E8879F637Q54987125-A8951B63-D371-4B76-A4D2-42E7B5B1B13EQ55269135-5E8C1BEF-FC6B-4738-9CFC-15BF838E2D50Q57529833-538BF9CB-CD50-4A2D-AE58-1A4AEBAA3189
P2860
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
@ast
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
@en
type
label
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
@ast
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
@en
prefLabel
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
@ast
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
@en
P2093
P2860
P356
P1476
Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses.
@en
P2093
Brett E Crawford
James R Beitel
Jeffrey D Esko
Jillian R Brown
Kanar Al-Mafraji
Roger Lawrence
William C Lamanna
P2860
P2888
P304
P356
10.1038/NCHEMBIO.766
P577
2012-01-08T00:00:00Z